Asclepius Medical Center OOD — Clinical Trial Site

36 Registered trials

11 Currently recruiting

Organisation

Asclepius Medical Center OOD

Location

Dupnitsa, Bulgaria

Identifier

ORG-100044880

Address

Ploshtad Svoboda 1, 2600, Bulgaria

Departments

Dermato-venerology
Dermatology
Endocrinology and Metabolic Diseases Consulting Room
N/A
NA
Office of Dermatology
Pneumonology and Phthisiaty Office
Pulmonology and Phtisiatrics

Clinical trials at this site (36)

Search interface

A Study to Learn About the Study Medicine Called PF-08049820 in People With Eczema, an Itchy Skin Rash Pending

2025-522965-31-00 Atopic Dermatitis 4
BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending

2025-524289-56-00 Asthma 6
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
A Phase 3 Study With Randomized Withdrawal/Dose Up Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants With… Recruiting

2023-505804-42-00 NON SEGMENTAL VITILIGO 5 2024-07-10
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting

2025-522642-44-00 CHRONIC SPONTANEOUS URTICARIA 4 2026-03-18
A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD Recruiting

2025-523020-50-00 Chronic Obstructive Pulmonary Disease 4 2026-03-04
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting

2025-520473-40-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 4 2025-09-29
A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting

2024-513171-41-00 Vitiligo 5 2025-09-11
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients with Coronavirus Disease 2019 (COVID-19) who ar… Recruiting

2024-517727-39-00 Covid-19 at high risk of progression to severe illness. 5 2025-07-28
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona… Recruiting

2024-517457-27-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2025-06-04
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
A Study Evaluating BFB759 in Atopic Dermatitis Ended

2025-521624-30-00 Atopic dermatitis 4 2026-01-08
A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended

2024-519743-15-00 Influenza immunisation 5 2025-10-20
A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended

2025-520521-21-00 Hyperlipidemia 5 2025-09-02
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended

2023-506011-18-00 Vitiligo 5 2024-04-17
A Study of Susceptibility to Baloxavir Marboxil in Patients with Influenza and its transmission to their household contacts Ended

2023-504672-22-00 Influenza 5 2023-11-24
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17